个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Clinical expert consensus on the assessment and protection of pancreatic islet β-cell function in type 2 diabetes mellitus

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhu Jian[1] ; Han Junfeng[2] ; Liu Liehua[3] ; Liu Yu[4] ; Xu Wen[5] ; Li Xiaomu[6] ; Yang Lin[7] ; Gu Yong[8] ; Tang Wei[9] ; Shi Yongquan[10] ; Ye Shandong[11] ; Hua Fei[12] ; Xiang Guangda[13] ; Liu Ming[14] ; Sun Zilin[15] ; Su Qing[16] ; Li Xiaoying[6] ; Li Yuxiu[17] ; Li Yanbing[3] ; Li Hong[18] ; Li Yiming[19] ; Yang Tao[8] ; Yang Jing[20] ; Shi Lixin[21] ; Yu Xuefeng[22] ; Chen Li[23] ; Shao Jiaqing[24] ; Liang Jun[25] ; Han Xiao[26] ; Xue Yaomin[27] ; Ma Jianhua[1] ; Zhu Dalong[28] ; Mu Yiming[29] ; On behalf of the Pancreatic Islet β-cell Expert Panel of the Chinese Diabetes Society and Endocrinology Society of Jiangsu Medical Association[1] ;
机构： [1]Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China. [2]Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Key Clinical Center for Metabolic Disease, Shanghai, China. [3]Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. [4]Endocrinology Department, Sir Run Run Hospital of Nanjing Medical University, Nanjing, China. [5]Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. [6]Department of Endocrine and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China. [7]National Clinical Research Center for Metabolic Diseases, Key Laboratory of Diabetes Immunology, Ministry of Education, Department of Metabolism and Endocrinology, The Second Xiangya Hospital of Central South University, Changsha, China. [8]Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. [9]Department of Endocrinology, Geriatric Hospital of Nanjing Medical University, Nanjing, China. [10]Department of Endocrinology, Changzheng Hospital, The Navy Military Medical University, Shanghai, China. [11]Department of Endocrinology, Anhui Provincial Hospital, Hefei, China. [12]Department of Endocrinology, The First People's Hospital of Changzhou, Changzhou, China. [13]Department of Endocrinology, General Hospital of Central Theater Command of Chinese People' s Liberation Army, Wuhan, China. [14]Department of Endocrinology, General Hospital, Tianjin Medical University, Tianjin, China. [15]Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University, Nanjing, China. [16]Department of Endocrinology, Xinhua Hospital, Shanghai Jiaotong University, Shanghai, China. [17]Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China. [18]Department of Endocrinology, First Affiliated Hospital of Kunming Medical University, Kunming, China. [19]Department of Endocrinology, Huashan Hospital, Fudan University, Shanghai, China. [20]Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, China. [21]Department of Endocrinology, Guiqian International General Hospital, Guiyang 550018, China. [22]Department of Endocrinology, Tongji Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, China. [23]Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, China. [24]Department of Endocrinology, the Affiliated Jinling Hospital of Nanjing Medical University, General Hospital of Eastern Theater Command, Nanjing, China. [25]Department of Endocrinology, Xuzhou Central Hospital, Xuzhou, China. [26]Key Laboratory of Human Functional Genomics of Jiangsu Province, School of Basic Medical Science, Nanjing Medical University, Nanjing, China. [27]The First Clinical Medical Institute, Southern Medical University, Guangzhou, China. [28]Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China. [29]Department of Endocrinology, Chinese PLA General Hospital, Beijing, China.
出处：
DOI： 10.1016/j.diabres.2023.110568
ISSN：

关键词： Islets β-cell Functional assessment

摘要：
Islet β-cell dysfunction is a basic pathophysiological characteristic of type 2 diabetes mellitus (T2DM). Appropriate assessment of islet β-cell function is beneficial to better management of T2DM. Protecting islet β-cell function is vital to delay the progress of type 2 diabetes mellitus. Therefore, the Pancreatic Islet β-cell Expert Panel of the Chinese Diabetes Society and Endocrinology Society of Jiangsu Medical Association organized experts to draft the "Clinical expert consensus on the assessment and protection of pancreatic islet β-cell function in type 2 diabetes mellitus." This consensus suggests that β-cell function can be clinically assessed using blood glucose-based methods or methods that combine blood glucose and endogenous insulin or C-peptide levels. Some measures, including weight loss and early and sustained euglycemia control, could effectively protect islet β-cell function, and some newly developed drugs, such as Sodium-glucose cotransporter-2 inhibitor and Glucagon-like peptide-1 receptor agonists, could improve islet β-cell function, independent of glycemic control.Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 3 区 医学
小类 | 3 区 内分泌学与代谢
JCR分区：
出版当年[2023]版：
Q1 ENDOCRINOLOGY & METABOLISM
最新[2023]版：
Q1 ENDOCRINOLOGY & METABOLISM

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Zhu Jian,Han Junfeng,Liu Liehua,et al.Clinical expert consensus on the assessment and protection of pancreatic islet β-cell function in type 2 diabetes mellitus[J].DIABETES RESEARCH AND CLINICAL PRACTICE.2023,197:doi:10.1016/j.diabres.2023.110568.
APA：
Zhu Jian,Han Junfeng,Liu Liehua,Liu Yu,Xu Wen...&On behalf of the Pancreatic Islet β-cell Expert Panel of the Chinese Diabetes Society and Endocrinology Society of Jiangsu Medical Association.(2023).Clinical expert consensus on the assessment and protection of pancreatic islet β-cell function in type 2 diabetes mellitus.DIABETES RESEARCH AND CLINICAL PRACTICE,197,
MLA：
Zhu Jian,et al."Clinical expert consensus on the assessment and protection of pancreatic islet β-cell function in type 2 diabetes mellitus".DIABETES RESEARCH AND CLINICAL PRACTICE 197.(2023)

相关文献

[1]LncRNA CCAT2 enhances cell proliferation via gsk3β/β-catenin signaling pathway in human Osteosarcoma [2]Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients [3]LncRNA CCAT2 enhances cell proliferation via GSK3β/β-catenin signaling pathway in human osteosarcoma. [4]A long noncoding RNA GTF2IRD2P1 suppresses cell proliferation in bladder cancer by inhibiting the Wnt/β-catenin signaling pathway [5]Associations of adipose insulin resistance index with pancreatic β cell function (inverse) and glucose excursion (positive) in young Japanese women [6]Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of β-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma [7]低氧血症对胰岛功能影响的临床探讨 [8]PTEN和β-cat在尖锐湿疣、Bowen's病和皮肤鳞癌中的表达及意义 [9]Low muscle mass is associated with low insulin sensitivity, impaired pancreatic β cell function, and high glucose excursion in nondiabetic nonobese Japanese women [10]miR-26a-5p Suppresses Wnt/β-Catenin Signaling Pathway by Inhibiting DNMT3A-Mediated SFRP1 Methylation and Inhibits Cancer Stem Cell-Like Properties of NSCLC

资源点击量：53661 今日访问量：0 总访问量：1665 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西昌路295号(650032)